Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Organon & Co (NYSE: OGN) closed the day trading at $10.12 down -2.79% from the previous closing price of $10.41. In other words, the price has decreased by -$2.79 from its previous closing price. On the day, 3.06 million shares were traded. OGN stock price reached its highest trading level at $10.38 during the session, while it also had its lowest trading level at $10.05.
Ratios:
For a better understanding of OGN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.00. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 12.14 whereas as Long-Term Debt/Eq ratio is at 11.98.
On September 06, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also upped its target price recommendation from $18 to $20.
Goldman Downgraded its Buy to Neutral on November 03, 2023, whereas the target price for the stock was revised from $33 to $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 14 ’25 when COX CARRIE SMITH bought 12,469 shares for $8.07 per share. The transaction valued at 100,591 led to the insider holds 12,469 shares of the business.
Falcione Aaron bought 5,500 shares of OGN for $48,235 on May 07 ’25. The Chief Human Resources Officer now owns 62,974 shares after completing the transaction at $8.77 per share. On May 06 ’25, another insider, Weaver Kirke, who serves as the Gen. Counsel & Corp. Secy. of the company, bought 8,045 shares for $9.21 each. As a result, the insider paid 74,054 and bolstered with 52,489 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OGN now has a Market Capitalization of 2630851584 and an Enterprise Value of 10927851520. As of this moment, Organon’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.76, and their Forward P/E ratio for the next fiscal year is 2.50. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 3.59. Its current Enterprise Value per Revenue stands at 1.74 whereas that against EBITDA is 6.516.
Stock Price History:
The Beta on a monthly basis for OGN is 0.58, which has changed by -0.47236705 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, OGN has reached a high of $19.73, while it has fallen to a 52-week low of $8.01. The 50-Day Moving Average of the stock is 3.66%, while the 200-Day Moving Average is calculated to be -16.10%.
Shares Statistics:
Over the past 3-months, OGN traded about 4.06M shares per day on average, while over the past 10 days, OGN traded about 4084760 shares per day. A total of 259.96M shares are outstanding, with a floating share count of 259.01M. Insiders hold about 0.37% of the company’s shares, while institutions hold 84.09% stake in the company. Shares short for OGN as of 1757894400 were 13694797 with a Short Ratio of 3.37, compared to 1755216000 on 14346223. Therefore, it implies a Short% of Shares Outstanding of 13694797 and a Short% of Float of 7.0199996.
Earnings Estimates
The current rating of Organon & Co (OGN) reflects the combined expertise of 5.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.88, with high estimates of $0.98 and low estimates of $0.72.
Analysts are recommending an EPS of between $3.94 and $3.69 for the fiscal current year, implying an average EPS of $3.83. EPS for the following year is $4.04, with 6.0 analysts recommending between $4.26 and $3.7.
Revenue Estimates
4 analysts predict $1.57B in revenue for the current quarter. It ranges from a high estimate of $1.59B to a low estimate of $1.52B. As of the current estimate, Organon & Co’s year-ago sales were $1.58BFor the next quarter, 4 analysts are estimating revenue of $1.59B. There is a high estimate of $1.64B for the next quarter, whereas the lowest estimate is $1.53B.
A total of 6 analysts have provided revenue estimates for OGN’s current fiscal year. The highest revenue estimate was $6.33B, while the lowest revenue estimate was $6.14B, resulting in an average revenue estimate of $6.27B. In the same quarter a year ago, actual revenue was $6.4BBased on 6 analysts’ estimates, the company’s revenue will be $6.32B in the next fiscal year. The high estimate is $6.41B and the low estimate is $6.19B.
